Because of the pivotal role of the CCL19/CCL21/CCR7 signaling axis in both antigen presentation and activation of T cell‐mediated responses, it has been postulated that increasing the levels of CCL19 and CCL21 within tumors could aid immunotherapy of cancer by enhancing the immune response to tumors. The gene discussed is CCR7; the disease is cancer.